Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Aisha > Dunedin- Haematology > Flashcards

Dunedin- Haematology Flashcards

1
Q

Describe anticoagulation and their targets

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How to manage elevated INR in adult patients

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe NOAC, there target, and potent drug interactions

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the effect of anticoagulation on PT and aPTT

A

rivaroxoban increases PT alot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe warfarin bridging before surgery:

A

*stop warfarin 5 days prior to surgery
*4 days prior check INR and start enoxaparen when INR is <2
*cease enoxaparen 24 hours before procedure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is acquired haemophilia A?

A

-Development of a clotting factor deficiency that was not present at birth
- usually due to an autoantibody to factor VIII
- usually present with significant bleeding into skin, muscles, soft tissues and mucous membranes

Lab
- prolonged APTT which does not correct with mixing study
- low level of factor VIII + inhibitor present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the management of acquired factor VIII inhibitors?

A

*recombinant activated Factor VII
*activated prothrombin complex concentrates (FEIBA-factor VIII inhibitor bypassing activity)

Immunosuppression: cyclophosphamide, rituximab, IVIG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the MOA of tranxemic acid?

A

Binds to plasminogen and prevents the breakdown of fibrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Management of cerebral vein thrombosis, splanchnic vein thrombosis

A

Cerebral vein thrombosis –> 3-6 months unless unprovoked in which case 6-12 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the MOA, eg and S/E of alkylating agents

A

Prevent cell division cross- linking strands of DNA–> prevent DNA synthesis–> programmed cell death

eg chlorambucil, cyclophosphamide, melphalan

S/E bone marrow depression, nausea and vomiting, late cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the MOA, e.g, S/E of antimetabolites

A

MOA: mimic normal cell components (in S phase) –>inhibit DNA replication

E.g folate methotrexate, pyrimidine: cytarabine

S/E: mucositis, bone marrow suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the MOA, e.g, S/E of anthracyclines

A

MOA: Many: free-radical formation, lipid peroxidation, direct membrane effects, enzyme interactions

Examples:
* Daunarubicin, Idarubicin,
doxorubicin

Side effects:
* Cardiotoxicity,
myelosuppression, alopecia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the MOA, e.g, S/E of topoisomerase II inhibitor

A

MOA: inhibits enzyme that manages the coiling of DNA –> accumulation

E.g. etoposide

S/E: diarrhoea, mucosal, nausea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the MOA of mitotic inhibitors, e.g, S/E

A

Mechanism: blocks microtubule formation –> prevents formation of mitotic spindle

E.g Vincristine

S/E: neurotoxicity, myelosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the MOA, E.g, S/E of BCL inhibitor

A

MOA: BCL-2 proteins are pro- an anti- apoptotic proteins that, in
cancer cells, are over expressed

E.g. Venetoclax

S/E TLS, neutropenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the MOA, E.g S/E of PL3K inhibitors?

A

MOA: PI3K/AKT/mTOR pathway is part of a signalling pathway for growth control, metabolism, translation initiation

Eg: idalalisib

S/E Autoimmune dysfunction, skin
toxicity, hypertension,
hyperglycaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the MOA of TKI inhibitors

A

Dont need mutation for it to work

Mechanism: Binds to BCR-ABL1 of oncoprotein BCR- ABL1

Examples: Imatanib, dasatinib, Nilotinib

S/E Hypertension,
diarrheoa, LV
dysfunction, QT
prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the MOA of proteasome inhibitors?

A

MOA: Proteosomes are structures
in cells that remove mis-
folded proteins and destroy
them. Blocking this causes
cell death

Examples: Bortezomib

S/E Peripheral neuropathy, Nausea, vomitting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe the MOA of monoclonal antibodies

A

MOA- cross-linking surface antigen –> cell death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Describe the lab results of Tumour Lysis syndrome

A

*Increased uric
acid
*Increased
potassium
*Increased
phosphate
*Decreased
calcium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the management of TLS

A

hydration
allopurinol –> reduces formation of new uric acid

Rasburicase –> converts uric acid to allantoin (readily excreted), rapidly decreases uric acid. therefore can deal with uric acid that is already formed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the most common indications for stem cell transplant

A

Autologous:
Multiple myeloma, non-hodgkins lymphoma, Hodgkins lymphoma

Allogenic
- AML, ALL, myelodysplastic syndrome, non-hodgkin lymphoma, Myeloproliferative neoplasms, severe aplastic anaemia
- BM failure, immunodeficiency (SCID), autoimmune disease, bone marrow disorders (haemoglobinopathies, thalassaemias, haemophilia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What problems arise if there is an issue with matching donor and recipient

A

if donor cells attack body –> GVHD

if host cells attack donor cell –> graft rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

MHC 1 and 2

A

Class 1:
- HLA-A, B-, C
- present on ALL cells

Class 2:
-HLA-DR, DQ, and DP, DM DO
- only on immune antigen presenting cells e.g dendritic cells, b cells, monocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Describe complications of allogenic transplant

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What is CAR-T cell therapy?

A

Chimeric antigen receptor T cell
take patients T-cells and re-program them and then give it back

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What are indications for CAR-T cell therapy

A

1) Relapsed refractory acute lymphoblastic leukaemia (ALL)

2) relapsed/refractory (R/R) DLBCL after failure of at least 2 prior line of therapy

3) R/R mantle cell lymphoma, after failure of therapy with a Bruton’s tyrosine kinase (BTK) inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are complications of CAR-T cell therapy?

A

Cytokine release syndrome (treatment symptomatic, tociluzimab, dexamethasone, methylprednisone)
- high fever and chills
- dyspnoea
- severe N/V and/or diarrhoea
- feeling dizzy or lightheaded
- headaches
- tachycardia
- fatigue
- muscle and/or joint pain

Neurotoxicity (dexamethasone, methylprednisone)
- headache
- confusion/agitation
- seizures
- dysphagia
- loss of balance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Describe pathogenesis of cytokine storm

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What is the most common lymphoma? and how is it managed

A

diffuse large B cell lymphoma

biopsy: mixture of large and small cells in a diffuse pattern with loss of architecture

treatment: R-CHOP
- rituximab
- cyclophosphamide
- doxorubicin (hydroxydaunorubicin)
- vincristine (oncovin)
- prednisone

+/- radiotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What are examples of myeloproliferative neoplasms and lab studies

A
  • polycythaemia vera
  • essential thrombocytosis
  • myelofibrosis
  • CML

PLETHORA

Lab studies:
- BCR:ABL for CML
- JAK2, Cal-R, MPL

Biopsy: hypercellular, fibrosis on reticulin stain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Myeloproliferative disease management?

A

CML –> TKI e.g imatinib, hydroxyurea

Polycythaemia –> phlebotomy, hydroxyurea

Essentail thrombocytosis –> hydroxyurea

Myelofibrosis
- JAK1/JAK2 –> ruxolitinib
- allogenic bone marrow transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

CLL investigations

A

*FBC: smudge/ smear cells
*Flow cytometry: dim surface immunoglobulin, CD5, CD19, CD20, and CD23
*FISH: del(13q14), del (11a), and del (17p)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

CLL treatment

A

1) watch and wait
2) treat if anaemia or thrombocytopenia, painful lymphadenopathy, B symptoms, lymphocyte doubling time, autoimmune haemolytic anaemia or ITP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What are indications of treatment of multiple myeloma

A

Indications for treatment
* >60% plasma cells
* Serum free light chains >100
*MRI lesions >5mm
* Hypercalcaemia
*Renal failure
* Anaemia
*Lytic lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Multiple myeloma treatment

A

Chemotherapy: bortezomib plus cyclophosphamide plus dexamethasone (VCD); bortezomib plus ow doxorubicin plus dexamethasone (PAD); and vincristine plus doxorubicin plus dexamethasone (VAD).

Non-chemotherapy regimens: Thalidomide/lenalidomide and dexamethasone, carfilzomib/bortezomib; daratumumab

Autologous stem cell transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What are aeur rods seen in?

A

AML particularly APML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Genetic abnormalities in AML

A

*t(8;21)(q22;q22),
* inv(16)(p13;q22),
* t(16;16)(p13;q22)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Describe the treatment approach for myelodysplastic syndrome

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What are investigations for follicular lymphoma

A

Biopsy:
* Nodular growth pattern
* Amount of centroblasts determine tumour grade
* Staining:, CD20 (or CD19), CD10, and BCL-6 and are negative for CD5 and CD23, BCL-2 (>85%)

Molecular genetics: genetics: t(14;18)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What is the clinical presentation of follicular lymphoma

A
  • painful adenopathy
  • may grow spontaneously grown and regress
    -usually asymptomatic otherwise
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What is the treatment for follicular lymphoma?

A

No standard treatment
* Involved regional radiotherapy –
especially if stage I or II disease
* Anti – CD 20: rituximab; Obinutuzumab plus chemotherapy

40
Q

What are causes of microcytosis

A

TAILS

Thalassaemia
Anaemia of chronic disease
iron deficiency anaemia
Lead posioning
Sideroblastic anaemia

41
Q

What does transfused iron deficiency look like on a film?

A

central pallor

42
Q

Describe anaemia of inflammation pathogenesis

A

infection/inflammation –> IL-6 –> increase hepcidin –> blocks ferroportin gate –> decreases Fe absorption in the gut, in the macrophages causes sequestration of Fe, therefore iron unavailable for Hb synthesis –> microcytic anaemia (functional iron deficiency)

43
Q

What does lead toxicity look like on a blood film?

A

Prominent basophilic stippling

44
Q

Regarding thalassaemia, what chromosomes are involved?

A

Alpha chains are from chromosome 16
Beta, gamma and other are chromosome 11

45
Q

Describe alpha thalassaemia

A
46
Q

Describe the clinical features of beta thalassaemia

A

*dependent on blood transfusions by definition
*expanded bone marrow, bone deformities
*hypersplenism
* hypercoagulable (VTE and cerebral)
*Iron overload –> cardiac failure and arrhythmias, delayed growth and puberty, chelation therapy (deferoxamine, deferiprone, deferasirox)

47
Q

Describe some thalassaemia combinations and ones that are better and worse

A

Better –> alpha and beta thalassaemia

Worse –> B Thal + HbE, HbS+Bthal worsens sickle train

48
Q

What does a blood film of B12/folate deficiency look like?

A

oval macrocyte, hypersegmented neutrophil, small RBCs (disordered erythopoiesis

49
Q

What are some causes of macrocytosis

A

*Excess alcohol
*liver disease
*myelodysplastic syndrome (including sideroblastic)
*B12/folate deficiency

Drugs: phenytoin, cytotoxic, anti-virals, trimethoprim

Reticulocytosis: haemolytic anaemia, bleeding

Myeloma (25% of cases), haemochromatosis, smoking

Aplastic anaemia

50
Q

What are causes of normocytic anaemia?

A

ABCD

A- acute blood loss
B- bone marrow failure
C- chronic disease
D- destruction (haemolysis)

51
Q

What is more common, extravascular or intravascular haemolysis?

A

Extravascular is more common (just means splenic haemolysis)

52
Q

What are causes of intravascular haemolysis?

A

*complement- mediated in paroxysmal nocturnal haemoglobinuria
*microangiopathic
*Heart values

53
Q

What do we expect to see in Autoimmune haemolytic anaemia?

A

this is IgG antibody mediated
Anaemia
reticulocytes
bilirubin (unconjugated)
Low haptoglobin
direct antiglobulin test (DAT; aka Coombs)

Pathogenesis: macrophages removing membrane from RBCs resulting in spherocytes

54
Q

What are Howell Jolly bodies?

A

These are basophilic nuclear remnants that occur post-splenectomy.

Other cells you can see post-splenectomy are target cells, spherocytes, odd cells

54
Q

What are causes of acquired hyposplenism?

A

1) infarction (sickle cell, essential thrombocythaemia, polycythaemia vera)

2) Atrophy/hypofunction: coeliac, dermatitis herpetiformis, IBD, autoimmune (SLE, RA, GN, PBC, Sjogren’s MCTD, thyroiditis), irradiation
- bone marrow transplantation & GVHD
- HIV/AIDS

3) Infiltration: amyloid, sarcoidosis, leukaemia, myeloproliferative

55
Q

What is the pathogenesis behind hereditary spherocytosis? And the mode of inheritance?

A

Mode of inheritance: Autosomal dominant

Occurs due to mutation sin Band 3, ankyrin, spectrin, and protein 4.2 –> this results in reduced surface-to-volume ratio –> reduced cellular deformability –> splenic destruction, anaemia

56
Q

Describe the genetics of G6PD, and what it looks like on a blood film

A

one the X-chromosome (affects males more)

Fava beans

Bite cells/keratocytes

56
Q

What are complications with hereditary spherocytosis?

A

*Cells trapped in spleen
*Anaemia
*life long excessive breakdown of haemologbin
*Pigment gallstones

splenectomy may be needed for cases with symptomatic anaemia

57
Q
A
57
Q
A
57
Q
A
58
Q
A
59
Q

Describe the pathophysiology of G6PD deficiency

A
59
Q

Describe some causes of drug-induced oxidative haemolysis

A

Dapsone
Sulphonamides
antimalarials
co-trimoxazole
naphthalene

60
Q

What are some images of toxic neutrophils

A
61
Q

What are causes of cold agglutinins?

A

IgM mediated
causes:
EBV, mycoplasma, lymphoma, DAT positive for C3d

most with cold agglutinin don’t have haemolytic anaemia but some do

62
Q

Describe the different forms of laboratory diagnostics we have for lymphoma

A

1) morphology of a lymph node, at times blood, spleen, marrow, skin

2) immunophenotyping (immunohistochemistry and/or flow cytometry)

3) FISH/cytogenetics occasionally

62
Q

Describe key blood film findings in different lymphoma

A

CLL –> smear/smudge cells

Peripheral T cell lymphoma –> the cleft and cerebriform cells of sezary syndrome/ peripheral T cell lymphoma

starry sky of burrito lymphoma

owl eye- Hodgkin lymphoma

63
Q

Describe the different cell surface markers

A

B cells –> CD19, CD20, either kappa or lambda

T cells –> CD3, CD4, CD5, CD8

Stem cells (e.g. leukaemia blasts) –> CD34

Granulocytes –> CD33, CD13, CD15

Monocytes –> CD14, CD64

63
Q

Describe abnormalities of von willebrand factor

A

VWF excess: TTP, HUS

VWF deficiency:
- genetic: von willebrand disease
- acquired: von willebrand syndrome (aortic stenosis and LV assist devices, essential thrombocythaemia, immune mediated, malignancy, hypothyroidism)

64
Q

Where are VWF secreted from?

A

Secreted from endothelial cells (Weibel-Palade bodies) in an ultra-large form

After secretion ultra-large multimeters are cleaved by ADAMT312 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 12)

failure to cleave leads to sticky WVF –> TTP

65
Q

Describe the pathophys behind TTP

A

Usually due to a transient, low level acquired autoantibody against ADAMTs13 (<10%)

Excessively long VWF multimers bind platelets, which activate clotting. Red cells are then fragmented by fibrin strands leading to microangiopathic haemolysis

66
Q

What is the treatment for TTP?

A

plasma exchange to replace the ADAMTs13 and to remove antibodies

67
Q

What is the relation of shiga toxin and HUS?

A

Shiga toxin binds the Gb3 receptor (more abundant in kidneys and in children) leading to endothelial injury

usually develop symptoms 2-14 days after onset of blood diarrhoea and severe crampy abdominal pain, accompanies by nausea and vomiting

68
Q

What is the different types of wVF disease?

A

Type 1- reduced LEVEL of VWF protein

Type 2- reduced function (activity <70% of expected for protein level)

Type 3- very low levels (both alleles affected)

69
Q

What are some functional tests for WVF?

A

1) VWF activity assay (VWF: GP1bM)- GP1b binding; replacing RCoF

2) Ristocetin co-factor activity (VWF: Rio)

3) Collagen binding assay (VWF: CB)

4) Factor VIII levels

70
Q

Lupus anticoagulant

A
71
Q

How to test for anti-cardiolipin and anti-b-2 glycoprotein 1

A

via enzyme immunoassay (EIA=ELISA)

72
Q

Anticoagulation of choice in anti-phospholipid syndrome?

A

warfarin

73
Q

Describe the 4T score for HITS

A

1) thrombocytopenia: drop >50%
2) timing of platelet count: on day 5-10 following heparin
3) thrombosis or other sequelae
4) no other cause of thrombocytopenia

74
Q

What chromosome is related to Haemophilia A and B?

A

X-chromosome

75
Q

Describe the severity of haemophilia A and B

A

severe <1 IU/dL (<1% of normal)

Moderate 1-5 IU/dL (ie. 1-5% of normal)

Mild 5-40 IU/dL (ie. 5-40% of normal)

75
Q

Describe the genetics of haemophilia A

A

Factor VIII

Most common defect: inversion of intron 22 in 40-45% of severe patients

Point mutations account for 67% of molecular defects, and small insertions and deletion represent 25%

76
Q

What is Emicizumab?

A

For haemophilia A
a bispecific antibody that mimics FVIII activity by binding to both activated-FIX & X, thereby activating FX (remember that FVIIIa is a co- factor for FIXa

Used for “severe” (<2%) haemophilia A

77
Q

What are some bypass agents in Haemophilia A

A

Activated prothrombin complex concentrate (aPCC) AKA FEIBA (contains factor 2, 7a, 9, and FX)

Bypass agents 2- recombinant F7A

78
Q

What is immune tolerance induction in Haemophilia A?

A

~30% of severe haemophilia A develop inhibitors (allo- antibodies), usually within the first 20-30 days

Immune tolerance induction is used to eradicate inhibitors and involves frequent injections of concentrates over many months

79
Q

What factor is involved in haemophilia B?

A

Factor 9

80
Q

What cells are involved in HLH?

A

Macrophages
Natural killer cells and cytotoxic lymphocytes
cytokine storm

81
Q

What most true about Factor VII?
A) deficiency typically prolonged APTT
B) FVIIa binds tissue factor
C) is a co-factor for factor VIII
D) acts as an anticoagulant
E) deficiency can be replaced with emicizumab

A

B) FVIIa binds tissue factor

82
Q

What is the MOA of Eltrombopag?

A

thrombopoietin-receptor-agonist

83
Q

Which of the following statements is true?

1.The pathological target of antiphospholipid antibodies is cardiolipin

  1. 80% correction in a 1:1 coag mixing study is suggestive of an antiphospholipid antibody

3.Correction of an APTT following addition of excess phospholipid is suggestive of a lupus anticoagulant

  1. Lupus anticoagulants are associated with bleeding
A

3.Correction of an APTT following addition of excess phospholipid is suggestive of a lupus anticoagulant

83
Q

A 16-year-old patient presents with mild jaundice, fatigue, and a family history of haemolytic anaemia. Blood tests reveal the following: haemoglobin 125 g/L, mean corpuscular volume (MCV) 85 fL, and reticulocyte count 5%. Examination of the peripheral blood smear is performed.
Which of the following findings is most characteristic of hereditary spherocytosis?

A) Target cells on peripheral smear
B) Positive direct antiglobulin test (DAT)
C) Elevated mean corpuscular hemoglobin concentration (MCHC)
D) Decreased osmotic fragility

A

C) Elevated mean corpuscular hemoglobin concentration (MCHC)

84
Q

Warm haemolytic anaemia vs cold

A

Warm- IgG
Cold- IgM

84
Q

What is chromosome 5q deletion associated with?

A

myelodysplastic syndrome
mx lenalidomide

85
Q

Describe the severity of haemophilia. Also the treatment

A

severe: 0-1%
moderate 1-5%
mild 5-30%

in mild-moderate haemophilia A, can give DDAVP peri-operatively

otherwise can give factor VIII

86
Q

In a patient with Budd Chiari syndrome, the most common underlying myeloproliferative disorder is:

A. CML
B. Chronic myelomonocytic leukaemia
C. Myelofibrosis
D. Essential Thrombocythaemia
E. Polycythaemia vera

A

E. Polycythaemia vera

87
Q

PNH piga gene affects what protein?

A. glycosylphosphatidyl-inositol
B. CD59
C. CD19

A

A. glycosylphosphatidyl-inositol

88
Q

Regarding AML, which genetic abnormalities are favourable?

A
89
Q
A

B- NPM-1

90
Q

Which of the following is the most sensitive test of rivaroxaban activity?
A) APTT
B) PT
C) Prothrombinase complex
D) Prothrombin products
E) INR

A

B- PT

note: apixaban is Xa levels, rivaroxoban is PT levels, dabigatran is thrombin time

Aisha (47 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions